|
Dramatic Potential Of Rotavirus Vaccines August 6, 2010, Path reports. New studies reveal dramatic potential of rotavirus vaccines in Asia and Africa Two new studies published today in the Lancet add to a growing body of evidence on the safety, efficacy, and lifesaving potential of rotavirus vaccines in low-income settings of Asia and Africa; where the virus takes its greatest toll. The studies, co-sponsored by the PATH Rotavirus Vaccine Program and conducted at clinical research sites in Ghana, Kenya, Mali, Bangladesh, and Vietnam, found that rotavirus vaccines
|
|
|
Inactivated Poliovirus Vaccines (IPV) PATH has released its study report on exploring feasibility of administrating IPV intradermally. Improving the Affordability of Inactivated Poliovirus Vaccines (IPV) for Use in Low- and Middle-Income Countries: An Economic Analysis of Strategies to Reduce the Cost of Routine IPV Immunization This report presents results from an economic model that calculates the costs involved in delivering IPV vaccine in Indian immunization clinics according to three strategies: (1) intradermal delivery of reduced volumes of vaccine per dose,
|
|
Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial The FUTURE I/II Study Group Correspondence to: J Dillner, Department of Medical Microbiology, Lund University, Malmö University Hospital, SE-20502 Malmö, Sweden
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Abstract Objectives To evaluate the prophylactic efficacy of the human papillomavirus (HPV) quadrivalent vaccine in preventing low grade cervical, vulvar, and vaginal intraepithelial neoplasias and anogenital warts (condyloma acuminata).
|
Recommendations for the Use of Rotavirus VaccinesMay 14, 2010 Summary FDA is updating its recommendations on both Rotarix and RotaTeq, vaccines for the prevention of rotavirus disease in infants. Based on careful evaluation of a variety of scientific information, FDA has determined it is appropriate for clinicians and health care professionals to resume the use of Rotarix and to continue the use of RotaTeq. Background On March 22, 20101, FDA provided an early communication regarding Rotarix, manufactured by GlaxoSmithKline
|
|
|
Ministry admits lapses in HPV vaccine trial TEENA THACKER NEW DELHI, DR V M Katoch, Secretary, Department of Health Research has admitted to the Parliamentary standing committee on Health and Family Welfare that Drug Controller General of India (DCGI) guidelines were not adhered to in the clinical trial of the Human Papilloma Virus (HPV) vaccine. A committee formed by the Union health ministry to probe the alleged violation of ethical guidelines is yet to submit its report.
|
|
SWINE FLU OUTBREAK 
Recently, human cases of swine influenza A (H1N1) virus infection have been recently reported in several countries. This is a novel  influenza A virus that has not been identified in people before, and human-to-human transmission of the virus appears to be ongoing and thus represents a real pandemic threat.
|
|
VACCINE COLD CHAIN Vaccines are among the most sensitive drugs that are administered into the body of healthy individuals. They are sensitive to heat and freezing hence they must be stored at the correct temperature right from the time they are manufactured till they are administered. This system of storage of vaccine or the medicine is known as cold chain. The potency of the vaccines can get affected irreversibly if the temperature is not maintained within the recommended range during the storage, transport, retailing and administering the vaccine. The recommended temperature range for most of the vaccine is from 2°C to 8°C however the range varies for the storage and transport, even long storage and short storage temperature also varies. Few vaccines are stored at a frozen state.
|
|
Last Updated on Saturday, 27 June 2009 14:00 |
|
|
Withdrawal of smallpox vaccine 'contributed to spread of HIV' Ending smallpox vaccination may have contributed to the explosive spread of HIV, scientists have claimed. The suggestion follows laboratory studies showing the vaccine's powerful ability to curb the Aids virus. It may have offered protection to people in the early days of the HIV epidemic, the findings suggest. But this would have been removed once smallpox was eradicated and the vaccine withdrawn. Smallpox immunisation was gradually phased out between the 1950s and 1970s. Since that time, rates of HIV infection have increased exponentially around the world. Scientists in the US studied white blood cells taken from people recently immunised with the smallpox vaccine, vaccinia. They found that immunisation led to a fivefold reduction in the ability of HIV to replicate in the cells.
|
|
Novel H1N1 Influenza: Resources for Clinicians Guidance for Patient Management Guidance for Specific Settings
|
|
VACCINE ADMINISTRATION Incorrectly administered vaccines, either incorrect sites or poor administration techniques, are contributing factors to vaccine failure and can lead to injection site nodules or lumps and local reactions. Proper knowledge of vaccine administration is very important for the vaccine provider and regular vaccine administration training programme should be held by the government or NGO bodies. Vaccination site; - Diphtheria, Tetanus, Pertussis, (DPT) Haemophilus Influenzae Type B (HIB), Hepatitis A and Hepatitis B components must be injected deep intramuscularly (IM)
- BCG is delivered intradermally
- MMR, measles IPV are injected subcutaneously (S/C)
- OPV and Rotavirus vaccines are given orally.
- Check the datasheet for administration of other vaccines
|
|
Last Updated on Saturday, 27 June 2009 02:03 |
|
|
